Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes
Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes
复制标题
DOI：
10.1111/jvh.12046
复制
发表时间：
2013-06-01
影响因子：
2.5
通讯作者：
Picchio, G.
中科院分区：
文献类型：
--
作者：
De Meyer, S.;Ghys, A.;Picchio, G.
C209研究评估了未接受治疗的2型或3型(G2、G3)丙型肝炎病毒(丙型肝炎病毒)感染患者的TELAPREVER活性。单一治疗显示出对丙型肝炎病毒G2的有效活性，但对G3的活性有限。这项分析是为了表征在基于telapvir的G2/G3型丙型肝炎病毒感染患者的治疗过程中出现的丙型肝炎病毒变异。患者被随机分成三组，分别接受两周的TELAPREVIR(单药治疗)、TELAPREVR加聚乙二胺干扰素-2a和利巴韦林(三联疗法)或安慰剂加聚乙二醇干扰素-2a和利巴韦林(对照组)的治疗，然后是2224周的单独使用聚乙二醇干扰素/利巴韦林。病毒突破的定义是丙型肝炎病毒RNA从最低点增加1log10，或以前达到
Study C209 evaluated the activity of telaprevir in treatment-naive patients with genotypes 2 or 3 (G2, G3) hepatitis C virus (HCV) infection. Telaprevir monotherapy showed potent activity against HCV G2, but limited activity against G3. This analysis was performed to characterize HCV viral variants emerging during telaprevir-based treatment of G2/G3 HCV-infected patients. Patients were randomized to receive 2weeks of treatment with telaprevir (telaprevir monotherapy), telaprevir plus peginterferon alfa-2a and ribavirin (triple therapy), or placebo plus peginterferon alfa-2a and ribavirin (control), followed by 2224weeks of peginterferon/ribavirin alone. Viral breakthrough was defined as an increase >1 log10 in HCV RNA from nadir, or HCV RNA >100IU/mL in patients previously reaching